J
Jan A. Burger
Researcher at University of Texas MD Anderson Cancer Center
Publications - 543
Citations - 33028
Jan A. Burger is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Chronic lymphocytic leukemia & Ibrutinib. The author has an hindex of 83, co-authored 511 publications receiving 28306 citations. Previous affiliations of Jan A. Burger include University of Texas Health Science Center at Houston & University of Freiburg.
Papers
More filters
Journal ArticleDOI
Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome
Gautam Borthakur,Zeev Estrov,Guillermo Garcia-Manero,Betsy Williams,Jay K. Wathen,Marina Konopleva,Jan A. Burger,Alessandra Ferrajoli,Solly George,Hagop M. Kantarjian +9 more
TL;DR: Combination of GO and Decitabine is effective and well tolerated particularly in patients with less heavily pre-treated AML/high-risk MDS and not eligible for intensive induction regimens.
Journal ArticleDOI
Chronic lymphocytic leukemia therapy: new targeted therapies on the way
Candida Vitale,Jan A. Burger +1 more
TL;DR: Preclinical and clinical data from phase I to III studies from promising new targeted drugs for CLL are presented in order to describe efficacy and side effect profile of these new drugs.
Journal ArticleDOI
Trisomy 12 is associated with an abbreviated redistribution lymphocytosis during treatment with the BTK inhibitor ibrutinib in patients with chronic lymphocytic leukaemia
Philip A. Thompson,Alessandra Ferrajoli,Susan O'Brien,William G. Wierda,Michael J. Keating,Jan A. Burger +5 more
TL;DR: The molecular basis of antithrombin deficiency in children and the risks of thrombosis in four coagulation defects associated with inheritedThrombophilia: a study of 150 families.
Journal ArticleDOI
Lenalidomide and Rituximab in Combination As Initial Treatment of Chronic Lymphocytic Leukemia: Initial Results of a Phase II Study
Philip A. Thompson,Michael J. Keating,Christina Hinojosa,Susan C. Smith,Naval Daver,Nitin Jain,Jan A. Burger,Zeev Estrov,Susan O'Brien,William G. Wierda,Hagop M. Kantarjian,Alessandra Ferrajoli +11 more
TL;DR: This study explored the combination of Len and rituximab in relapsed CLL with results suggesting TN pts could derive greater benefit than relapsed pts from Len + R given their less compromised immune function and a trend toward inferior ORR for patients with complex metaphase cytogenetics.
Journal ArticleDOI
Mobilization and elimination of FLT3-ITD+ acute myelogenous leukemia (AML) stem/progenitor cells by plerixafor, G-CSF, and sorafenib: Phase I trial results in relapsed/refractory AML patients.
Michael Andreeff,Gautam Borthakur,Zhihong Zeng,Mary A. Kelly,Rui-Yu Wang,Teresa McQueen,Yihua Qiu,Duncan Mak,Jan A. Burger,Naval Daver,Naveen Pemmaraju,Tapan M. Kadia,Elias Jabbour,Sherry Pierce,Farhad Ravandi,Guillermo Garcia-Manero,Susan O'Brien,Jorge E. Cortes,Hagop M. Kantarjian,Marina Konopleva +19 more
TL;DR: The group identified sorafenib (S) as potent inhibitor of FLT3-ITD mutant AML and demonstrated increased preclinical activity of S, which is associated with poor prognosis.